Search research articles
Contact Us
Filters
Showing results (111-120 of 122) with videos related to
Page
of 13
Sort By:
Oncology Letters
|
March 7, 2024
Efficacy of nab‑paclitaxel vs. Gemcitabine in combination with S‑1 for advanced pancreatic cancer: A multicenter phase II randomized trial
Xi Guo, Wenhui Lou, Yaolin Xu, et al.
BMC Medicine
|
July 6, 2025
Phase 1 trial of HR070803 (an Irinotecan liposome) in combination with 5-fluorouracil, leucovorin, and oxaliplatin for untreated advanced or metastatic pancreatic ductal adenocarcinoma
Qiang Xu, Xue Zhao, Xianze Wang, et al.
International Journal of Oncology
|
August 29, 2015
Should a standard lymphadenectomy during pancreatoduodenectomy exclude para-aortic lymph nodes for all cases of resectable pancreatic head cancer? A consensus statement by the Chinese Study Group for Pancreatic Cancer (CSPAC)
Chen Liu, Rufu Chen, Yingtai Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 30, 2023
Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic Cancer
Shukui Qin, Jin Li, Yuxian Bai, et al.
Cancer Communications (London, England)
|
November 25, 2021
Characterization of DNA damage response deficiency in pancreatic cancer patients from China
Xiaofei Zhang, Tiebo Mao, Bei Zhang, et al.
International Journal of Oncology
|
January 1, 2016
The clinical utility of CA125/MUC16 in pancreatic cancer: A consensus of diagnostic, prognostic and predictive updates by the Chinese Study Group for Pancreatic Cancer (CSPAC)
Liang Liu, Jinfeng Xiang, Rufu Chen, et al.
Ebiomedicine
|
March 1, 2022
Characterization of the genomic landscape in large-scale Chinese patients with pancreatic cancer
Xiaofei Zhang, Tiebo Mao, Bei Zhang, et al.
Signal Transduction and Targeted Therapy
|
September 19, 2024
Irinotecan hydrochloride liposome HR070803 in combination with 5-fluorouracil and leucovorin in locally advanced or metastatic pancreatic ductal adenocarcinoma following prior gemcitabine-based therapy (PAN-HEROIC-1): a phase 3 trial
Jiujie Cui, Shukui Qin, Yuhong Zhou, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 26, 2025
Tecotabart vedotin in Claudin 18.2-positive advanced gastric/gastroesophageal junction cancer: A Bayesian phase 1/2 clinical trial
Chunmei Bai, Yi Zheng, Meili Sun, et al.
International Journal of Oncology
|
December 31, 2016
Surgery management for sporadic small (≤2 cm), non-functioning pancreatic neuroendocrine tumors: a consensus statement by the Chinese Study Group for Neuroendocrine Tumors (CSNET)
Guang Yang, Meng Ji, Jie Chen, et al.
Page
of 13
Search research articles
Search
Showing results (111-120 of 122) with videos related to
Sort By:
Page
of 13
Oncology Letters
|
March 7, 2024
Efficacy of nab‑paclitaxel vs. Gemcitabine in combination with S‑1 for advanced pancreatic cancer: A multicenter phase II randomized trial
Xi Guo, Wenhui Lou, Yaolin Xu, et al.
BMC Medicine
|
July 6, 2025
Phase 1 trial of HR070803 (an Irinotecan liposome) in combination with 5-fluorouracil, leucovorin, and oxaliplatin for untreated advanced or metastatic pancreatic ductal adenocarcinoma
Qiang Xu, Xue Zhao, Xianze Wang, et al.
International Journal of Oncology
|
August 29, 2015
Should a standard lymphadenectomy during pancreatoduodenectomy exclude para-aortic lymph nodes for all cases of resectable pancreatic head cancer? A consensus statement by the Chinese Study Group for Pancreatic Cancer (CSPAC)
Chen Liu, Rufu Chen, Yingtai Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 30, 2023
Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic Cancer
Shukui Qin, Jin Li, Yuxian Bai, et al.
Cancer Communications (London, England)
|
November 25, 2021
Characterization of DNA damage response deficiency in pancreatic cancer patients from China
Xiaofei Zhang, Tiebo Mao, Bei Zhang, et al.
International Journal of Oncology
|
January 1, 2016
The clinical utility of CA125/MUC16 in pancreatic cancer: A consensus of diagnostic, prognostic and predictive updates by the Chinese Study Group for Pancreatic Cancer (CSPAC)
Liang Liu, Jinfeng Xiang, Rufu Chen, et al.
Ebiomedicine
|
March 1, 2022
Characterization of the genomic landscape in large-scale Chinese patients with pancreatic cancer
Xiaofei Zhang, Tiebo Mao, Bei Zhang, et al.
Signal Transduction and Targeted Therapy
|
September 19, 2024
Irinotecan hydrochloride liposome HR070803 in combination with 5-fluorouracil and leucovorin in locally advanced or metastatic pancreatic ductal adenocarcinoma following prior gemcitabine-based therapy (PAN-HEROIC-1): a phase 3 trial
Jiujie Cui, Shukui Qin, Yuhong Zhou, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 26, 2025
Tecotabart vedotin in Claudin 18.2-positive advanced gastric/gastroesophageal junction cancer: A Bayesian phase 1/2 clinical trial
Chunmei Bai, Yi Zheng, Meili Sun, et al.
International Journal of Oncology
|
December 31, 2016
Surgery management for sporadic small (≤2 cm), non-functioning pancreatic neuroendocrine tumors: a consensus statement by the Chinese Study Group for Neuroendocrine Tumors (CSNET)
Guang Yang, Meng Ji, Jie Chen, et al.
Page
of 13